Article Date

PM Group's Boston team is excited to be working with Resilience, a newly formed CDMO (Contract Development and Manufacturing Organisation), on its recently acquired facility (formerly Sanofi-Genzyme) in Allston, MA.

Multi-modality manufacturing

Resilience is focused on providing new, better, faster ways to manufacture cell and gene therapies. The company is actively investing in developing powerful new technologies to manufacture complex medicines that are defining the future of therapeutics including cell and gene therapies, viral vectors, vaccines and proteins.

“We are assisting with design for the facility which will have multi-modality manufacturing and state-of-the-art quality labs.” said Donal O’Mahony, General Manager, PM Group - Boston.

“Applying the latest bioprocess manufacturing platform designs in Boston’s iconic biotech building, formerly Genzyme’s ‘Cathedral on the Charles’, we’re delighted to support Resilience in delivering this exciting project,” added Gerard O’Donoghue, Office Projects Manager, PM Group - Boston.

Want to know more?

Contact our Boston team.
Contact our Boston team.

Contact our Boston team.